The World Health Organization (WHO) has declared the end of Ebola virus transmission in the Republic of Guinea. Consider the following statements:
1. World Health Organisation (WHO) approved the ReEBOV Antigen rapid test kit for Ebola virus disease (EVD).
2. Camels are considered to be the natural host of the Ebola virus.
3. Ebola first appeared in 1976, in Nzara and Sudan. Later it was reported in Yambuku, Democratic Republic of Congo.
Select the correct answer from the code given below:
The World Health Organization (WHO) has declared the end of Ebola virus transmission in the Republic of Guinea. Consider the following statements:
1. World Health Organisation (WHO) approved the ReEBOV Antigen rapid test kit for Ebola virus disease (EVD).
2. Camels are considered to be the natural host of the Ebola virus.
3. Ebola first appeared in 1976, in Nzara and Sudan. Later it was reported in Yambuku, Democratic Republic of Congo.
Select the correct answer from the code given below:
The correct option is D Only 1 & 3 are true
The World Health Organization (WHO) declared the end of Ebola virus transmission in the Republic of Guinea.Ebola first appeared in 1976, in Nzara and Sudan. Later it was reported in Yambuku, Democratic Republic of Congo.
Ebola Virus Disease (EVD) is formerly known as Ebola haemorrhagic fever. It is a severe and often fatal illness in humans. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. No licensed specific treatment or vaccine is available for use in people or animals.
EVD outbreaks occur primarily in remote villages in Central and West Africa, near tropical rainforests. Fruit bats of the Pteropodidae family are considered to be the natural host of the Ebola virus.
Symptoms
EVD is a severe acute viral illness often characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding.
World Health Organisation (WHO) approved the ReEBOV Antigen rapid test kit for Ebola virus disease (EVD) which can give the result in 15 minutes.
The test kit developed by Corgenix in the United States (US) has been approved for use in West African nations.
Characteristic Features of ReEBOV Antigen rapid test kit
1.It is quick and easy test which can be used in rural African settings
2. The test simply detects the Ebola protein instead of testing for the genetic material of the virus – its nucleic acid.
3. It is less definitive, but it can correctly identify about 92 percent of Ebola-infected patients and 85 percent of those not infected with the virus.
4.The test is small, cheap and portable but is less sensitive than the gold-standard test that is used to diagnose early-stage Ebola.
Only 1 & 3 are true
The World Health Organization (WHO) declared the end of Ebola virus transmission in the Republic of Guinea.Ebola first appeared in 1976, in Nzara and Sudan. Later it was reported in Yambuku, Democratic Republic of Congo.
Ebola Virus Disease (EVD) is formerly known as Ebola haemorrhagic fever. It is a severe and often fatal illness in humans. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. No licensed specific treatment or vaccine is available for use in people or animals.
EVD outbreaks occur primarily in remote villages in Central and West Africa, near tropical rainforests. Fruit bats of the Pteropodidae family are considered to be the natural host of the Ebola virus.
Symptoms
EVD is a severe acute viral illness often characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding.
World Health Organisation (WHO) approved the ReEBOV Antigen rapid test kit for Ebola virus disease (EVD) which can give the result in 15 minutes.
The test kit developed by Corgenix in the United States (US) has been approved for use in West African nations.
Characteristic Features of ReEBOV Antigen rapid test kit
1.It is quick and easy test which can be used in rural African settings
2. The test simply detects the Ebola protein instead of testing for the genetic material of the virus – its nucleic acid.
3. It is less definitive, but it can correctly identify about 92 percent of Ebola-infected patients and 85 percent of those not infected with the virus.
4.The test is small, cheap and portable but is less sensitive than the gold-standard test that is used to diagnose early-stage Ebola.
